Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Najemnik

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Wiener Medizinische Wochenschrift (1946)|May 15, 1983
[Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients]H Kritz, C Najemnik, K Irsigler
Acta Medica Austriaca|August 22, 2001
Endothelial dysfunction, atherosclerosis and diabetesC Najemnik, H Sinzinger, H Kritz
Wiener Klinische Wochenschrift|June 4, 1999
Tea--a potent agent to prevent disease?C Najemnik, H Sinzinger, H Kritz
Pharmacological Research Communications|September 1, 1981
Pilot study of pirinixil (BR 931) in various forms of hyperlipoproteinemiasC Najemnik, K Irsigler, C R Sirtori
Arzneimittel-Forschung|January 1, 1981
Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II bC Najemnik, H Lageder, H Regal, et al.
Wiener Klinische Wochenschrift|April 11, 1980
[Regression of florid proliferative diabetic retinopathy through achievement of normoglycaemic over five months by means of a portable insulin-dosage apparatus (author's transl)]K Irsigler, H Kirtz, C Najemnik, et al.
Lancet (London, England)|November 17, 1979
Reversal of florid diabetic retinopathyK Irsigler, H Kritz, C Najemnik, et al.
Diabetes Research (Edinburgh, Scotland)|July 1, 1984
Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid")I W Campbell, H Kritz, C Najemnik, et al.
Journees Annuelles De Diabetologie De L'Hotel-Dieu|January 1, 1983
[Implantable fixed continuous flow pumps in type I diabetes (insulin-dependent diabetes)]K Irsigler, H Kritz, C Najemnik, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|November 25, 2000
Association of lipoprotein(a), prostaglandin I(2)--synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stagesH Kritz, Y Efthimiou, J Stamatopoulos, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Wiener Medizinische Wochenschrift (1946)|May 15, 1983
[Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients]H Kritz, C Najemnik, K Irsigler
Acta Medica Austriaca|August 22, 2001
Endothelial dysfunction, atherosclerosis and diabetesC Najemnik, H Sinzinger, H Kritz
Wiener Klinische Wochenschrift|June 4, 1999
Tea--a potent agent to prevent disease?C Najemnik, H Sinzinger, H Kritz
Pharmacological Research Communications|September 1, 1981
Pilot study of pirinixil (BR 931) in various forms of hyperlipoproteinemiasC Najemnik, K Irsigler, C R Sirtori
Arzneimittel-Forschung|January 1, 1981
Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II bC Najemnik, H Lageder, H Regal, et al.
Wiener Klinische Wochenschrift|April 11, 1980
[Regression of florid proliferative diabetic retinopathy through achievement of normoglycaemic over five months by means of a portable insulin-dosage apparatus (author's transl)]K Irsigler, H Kirtz, C Najemnik, et al.
Lancet (London, England)|November 17, 1979
Reversal of florid diabetic retinopathyK Irsigler, H Kritz, C Najemnik, et al.
Diabetes Research (Edinburgh, Scotland)|July 1, 1984
Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid")I W Campbell, H Kritz, C Najemnik, et al.
Journees Annuelles De Diabetologie De L'Hotel-Dieu|January 1, 1983
[Implantable fixed continuous flow pumps in type I diabetes (insulin-dependent diabetes)]K Irsigler, H Kritz, C Najemnik, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|November 25, 2000
Association of lipoprotein(a), prostaglandin I(2)--synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stagesH Kritz, Y Efthimiou, J Stamatopoulos, et al.
Pageof 2